Diagnostic and prognostic factors in patients with prostate cancer

被引：0

作者：

Beyer, K. ^{[1
]}

Moris, L. ^{[2
]}

Lardas, M. ^{[3
]}

Haire, A. ^{[1
]}

Barletta, F. ^{[4
]}

Scuderi, S. ^{[4
]}

Molnar, M. ^{[5
]}

Herrera, R. ^{[5
]}

Rauf, A. ^{[6
]}

Campi, R. ^{[7
]}

Greco, I. ^{[7
]}

Shiranov, K. ^{[8
]}

Dabestani, S. ^{[9
]}

Van den Broeck, T. ^{[2
]}

Gacci, M. ^{[7
]}

Gandaglia, G. ^{[4
]}

Omar, M. I. ^{[10
]}

Maclennan, S. ^{[10
]}

Roobol, M. J. ^{[11
]}

Zong, J. ^{[12
]}

Maclennan, S. J. ^{[10
]}

Collette, L. ^{[13
]}

Briganti, A. ^{[14
]}

Bjartell, A. ^{[15
]}

Van Hemelrijck, M. ^{[1
]}

机构：

[1] Kings Coll London, Translat & Oncol Res TOUR, London, England

[2] Univ Hosp Leuven, Dept Urol, Leuven, Belgium

[3] Metropolitan Gen, Dept Urol, Athens, Greece

[4] IRCCS Osped San Raffaele, Unit Urol, Div Oncol, URI, Milan, Italy

[5] Bayer AG, Dept Epidemiol, Berlin, Germany

[6] NHS Fdn Trust, Mid Cheshire Hosp, Dept Urol, Crewe, England

[7] Univ Florence, Dept Minimally Invas & Robot Urol Surg & Kidney T, Florence, Italy

[8] Zdorovie, CDC, Rostov Na Donu, Russia

[9] Lund, Div Urol Canc, Dept Translat Med, Kristianstad Cent Hosp, Malmo, Sweden

[10] Univ Aberdeen, Acad Urol Unit, Aberdeen, Scotland

[11] Erasmus MC, Dept Urol, Rotterdam, Netherlands

[12] Bayer HealthCare Pharmaceut Inc, Global Med Affairs Oncol, Real World Evidence, Whippany, NJ USA

[13] EORTC, Brussels, Belgium

[14] Univ Vita & Salute San Raffaele, Dept Urol, Milan, Italy

[15] Lund Univ, Dept Translat Med, Malmo, Sweden

来源：

EUROPEAN UROLOGY | 2021年 / 79卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

P0299

引用

页码：S428 / S429

页数：2

共 50 条

[31] Genetic alterations in prostate cancer as diagnostic and prognostic markers
Saeidi, Hamidreza
Ismail, Patimah
Samudi Raju, Chandramathi
Khairul-Asri, Mohd Ghani
Bakrin, Ikmal Hisyam
[J]. MALAYSIAN JOURNAL OF PATHOLOGY, 2023, 45 (02) : 149 - 155
[32] MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in Prostate Cancer
Aghdam, Arad Mobasher
Amiri, Atefeh
Salarinia, Reza
Masoudifar, Aria
Ghasemi, Faezeh
Mirzaei, Hamed
[J]. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2019, 29 (02): : 127 - 139
[33] Prognostic and predictive clinical factors for progression to castration refractory prostate cancer in patients with hormone sensitive prostate cancer
Watanabe, M.
Kanao, K.
Sugie, M.
Morinaga, S.
Muramatsu, H.
Kobayashi, I.
Kajikawa, K.
Nishikawa, G.
Zennami, K.
Nakamura, K.
Sumitomo, M.
[J]. ANNALS OF ONCOLOGY, 2018, 29 : 73 - 73
[34] Molecular and genetic prognostic factors of prostate cancer
Chakravarti, A
Zhai, GG
[J]. WORLD JOURNAL OF UROLOGY, 2003, 21 (04) : 265 - 274
[35] PROGNOSTIC FACTORS OF METASTASIS FOR NONPALPABLE PROSTATE CANCER
Samycha, J.
Chaidir, A. M.
Rainy, U.
[J]. INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 280 - 280
[36] Molecular and genetic prognostic factors of prostate cancer
Arnab Chakravarti
Gary Guotang Zhai
[J]. World Journal of Urology, 2003, 21 : 265 - 274
[37] PROGNOSTIC FACTORS IN METASTATIC PROSTATE-CANCER
MATZKIN, H
PERITO, PE
SOLOWAY, MS
[J]. CANCER, 1993, 72 (12) : 3788 - 3792
[38] Prognostic factors in the pathological assessment of prostate cancer
Murphy, WM
[J]. HUMAN PATHOLOGY, 1998, 29 (05) : 427 - 430
[39] Immunopathological prognostic and predictive factors in prostate cancer
Sivridis E.
Touloupidis S.
Giatromanolaki A.
[J]. International Urology and Nephrology, 2002, 34 (1) : 63 - 71
[40] Molecular biomarkers and prognostic factors for prostate cancer
Kretschmer, A.
Tolkach, Y.
Ellinger, J.
Kristiansen, G.
[J]. UROLOGE, 2017, 56 (07): : 933 - 943

← 1 2 3 4 5 →